Evidence map›Paper›PMID 26733290›Full record

ArticleEuropean journal of human genetics : EJHG2016

A novel splicing mutation in the IQSEC2 gene that modulates the phenotype severity in a family with intellectual disability.

Irene Madrigal, Maria Isabel Alvarez-Mora, Jordi Rosell, Laia Rodríguez-Revenga, Olof Karlberg, Sascha Sauer, Ann-Christine Syvänen, Montserrat Mila

Open access · bronzeAbstract read
In one paragraph

Article in European journal of human genetics : EJHG, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.0field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Molecular Insights into IQSEC2 Disease.International journal of molecular sciences · 2023
    Review
  2. Differences in Expression ofInternational journal of molecular sciences · 2022
    Article
  3. Article
  4. IQSEC2-related encephalopathy in males and females: a comparative study including 37 novel patients.Genetics in medicine : official journal of the American College of Medical Genetics · 2019
    Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 7 institutions in 3 countries.

Irene MadrigalBiochemistry and Molecular Genetics Department, Hospital Clínic and IDIBAPS, Barcelona, Spain.
Maria Isabel Alvarez-MoraBiochemistry and Molecular Genetics Department, Hospital Clínic and IDIBAPS, Barcelona, Spain.
Jordi RosellGenetics Section, Hospital Universitari Son Espases, Palma de Mallorca, Spain.
Laia Rodríguez-RevengaBiochemistry and Molecular Genetics Department, Hospital Clínic and IDIBAPS, Barcelona, Spain.
Olof KarlbergDepartment of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Sascha SauerMax-Planck Institute for Molecular Genetics Ihnestrasse, Berlin, Germany.
Ann-Christine SyvänenDepartment of Medical Sciences, Molecular Medicine and Science for Life Laboratory, Uppsala University, Uppsala, Sweden.
Montserrat MilaBiochemistry and Molecular Genetics Department, Hospital Clínic and IDIBAPS, Barcelona, Spain.
Hospital Clínic de Barcelona · ESCentre for Biomedical Network Research on Rare Diseases · ESConsorci Institut D'Investigacions Biomediques August Pi I Sunyer · ESHospital Universitario Son Espases · ESMax Planck Institute for Molecular Genetics · DEScience for Life Laboratory · SEUppsala University · SE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The IQSEC2 gene is located on chromosome Xp11.22 and encodes a guanine nucleotide exchange factor for the ADP-ribosylation factor family of small GTPases. This gene is known to have a significant role in cytoskeletal organization, dendritic spine morphology and synaptic organization. Variants in IQSEC2 cause moderate to severe intellectual disability in males and a variable phenotype in females because this gene escapes from X-chromosome inactivation. Here we report on the first splicing variant in IQSEC2 (g.88032_88033del; NG_021296.1) that co-segregates in a family diagnosed with an X-linked form of ID. In a percentage of the cells, the variant activates an intraexonic splice acceptor site that abolishes 26 amino acids from the highly conserved PH domain of IQSEC2 and creates a premature stop codon 36 amino acids later in exon 13. Interestingly, the percentage of aberrant splicing seems to correlate with the severity of the disease in each patient. The impact of this variant in the target tissue is unknown, but we can hypothesize that these differences may be related to the amount of abnormal IQSEC2 transcript. To our knowledge, we are reporting a novel mechanism of IQSEC2 involvement in ID. Variants that affect splicing are related to many genetic diseases and the understanding of their role in disease expands potential opportunities for gene therapy. Modulation of aberrant splicing transcripts can become a potent therapeutic approach for many of these diseases.

Indexed as

MutationPhenotypeAdultCells, CulturedCodon, TerminatorFemaleGuanine Nucleotide Exchange FactorsHumansIntellectual DisabilityMaleMiddle AgedPedigreeRNA SplicingCodon, TerminatorGuanine Nucleotide Exchange FactorsIQSEC2 protein, human

Identifiers

PMID26733290
PMCPMC4970682
OpenAlexW2225829779

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.